Phase I Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Pancreatic Cancer.

Trial Profile

Phase I Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Erlotinib (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 03 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2018 as reported by ClinicalTrials.gov.
    • 04 Sep 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D.Anderson record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top